Clinical trial
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast…
NCT00185276 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185276 |
|---|---|
| Title | Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries |
| Official title | Randomized, Multi-center Open Label Study of the Safety (Open-label) and Efficacy (Open-label & Blinded Reader) of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) at Two Dose Levels and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients Undergoing MRA of the Infrarenal Aorta… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Gadopentetate dimeglumine (Magnevist, BAY86-4882) |
| Enrollment | 365 |
| Start date | Mar 1, 2003 |
| Completion | Aug 1, 2004 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 30, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: